Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiju Dihuang Pill (QJDHW) is a classical Traditional Chinese Medicine (TCM) formulation primarily used to treat ocular conditions associated with Liver and Kidney Yin deficiency. It is an extension of the Liuwei Dihuang Wan formula, enriched with *Lycium chinense* (Gou Qi Zi) and *Chrysanthemum morifolium* (Ju Hua) to specifically target eye health. Clinical and preclinical evidence indicates that QJDHW manages age-related dry eye disease (DED) by modulating the complement system, reducing ocular surface inflammation, and stabilizing the tear film. It is widely manufactured by various TCM pharmaceutical companies, most notably Beijing Tongrentang, and is typically administered orally as concentrated pills or water-honey pills.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qiju Dihuang Pill.